Evening Brief: TCM Innovation Heats Up, Ainos Tech Closes Series C+ Round, HKEX Opens Lower as WuXi AppTec Jumps Over 4% on Clarification

1. Innovation in Traditional Chinese Medicine is "Heating Up," a TCM CXO Company Announces Completion of RMB 10 Million Financing

Hangzhou Traditional Chinese Medicine CXO Company Junheng Pharmaceuticals Secures Tens of Millions of Yuan in Angel Round Funding from Huafang Capital for Innovative TCM Development Platform Construction and Talent Expansion, Aiming to Promote the Development of Innovative TCM Drugs and Hospital Formulations. In recent years, favorable TCM policies, a surge in TCM innovation, and frequent financing events in the CXO industry have been observed.

2. Ainos Technology Completes C+ Round Financing, Invested by Yingchuan Capital and Huaxia Zhixun

Ainos Technology Completes C+ Round Financing, Secures Investment from Yingchuan Capital and Huaxia Zhixun for AI Research in Eye Health and School Hygiene Informatization. The company has developed a vision monitoring system based on IoT, AI and other technologies, which has been widely applied across China.

3. This pharmaceutical company is accelerating its entry into the international market, with another drug receiving FDA approval

Lunan Pharmaceutical Group's Shandong New Era Pharmaceutical Isosorbide Mononitrate Extended-Release Tablets Receive FDA Approval; Three Specifications Can Be Sold in the U.S.

4. Healing Pharmaceutical Completes Nearly 200 Million Yuan B+ Round Financing

Hope Medicine Completes Nearly 200 Million Yuan B+ Round Financing, Led by Xiangtan Venture Capital and VMS Group, to Support International Phase II Clinical Trials of Its Core Pipeline HMI-115 Antibody and Other R&D. Hope Medicine is an innovative biopharmaceutical company focusing on first-in-class drug development in women's health, endocrinology, and cardiovascular diseases, and has collaborated with Bayer to develop HMI-115.

5. Hong Kong's Hang Seng Index opened 0.03% lower, tech index fell 0.68%; WuXi AppTec surged over 4% after further clarification

On February 19, Hong Kong stocks opened lower, with technology shares generally falling, while WuXi AppTec opened more than 4% higher. U.S. stocks fell last Friday, and this week's focus will be on the earnings reports of companies such as Nvidia. Hong Kong stocks showed improvement last week, with the Hang Seng Index reclaiming the 16,000-point level. The reopening of China's A-share market is expected to start positively, and the Hang Seng Index may maintain its rebound momentum.

6. Jacobio's SHP2 Inhibitor + KRAS G12C Inhibitor Phase III Clinical Trial Approved by CDE

Jacobio's Self-Developed SHP2 Inhibitor JAB-3312 in Combination with KRAS G12C Inhibitor Gorletrectinib Approved for Phase III Clinical Trial in China to Evaluate Efficacy and Safety in First-Line Non-Small Cell Lung Cancer Patients